Targeted treatment plus low-dose chemo for new B-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of a targeted drug and low-dose chemotherapy for adults newly diagnosed with a certain type of acute lymphoblastic leukemia (ALL). The goal is to find a gentler but effective treatment that may be easier for patients to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and newly diagnosed with B-cell acute lymphoblastic leukemia that does not have the Philadelphia chromosome (Ph-negative).
- Your leukemia cells must have a protein called CD22 on at least 20% of them—your doctor can test this.
- Your doctor expects you to live at least 3 months, regardless of the leukemia.
- If you are sexually active and able to have children, you must agree to use effective birth control during the study.
- You must be willing to sign a consent form and follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a targeted antibody therapy with a low dose of chemotherapy to treat adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combo can help shrink or eliminate the leukemia with fewer side effects than standard treatment.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
This trial tests giving chemotherapy together with a special immune cell treatment called CAR-T cells for adults who have just been diagnosed with a specific type of leukemia (Ph- B-ALL). The goal is to see if this combination works better than standard treatment.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Hear when a new Ph- Acute Lymphoblastic Leukemia (Ph-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.